Ironwood Pharma jumps after 2026 revenue forecast above estimates

Ironwood Pharmaceuticals

02/01/2026 12:30

** Shares of drugmaker Ironwood Pharmaceuticals IRWD.O rise 20.2% to $4.05 premarket

** IRWD expects 2026 annual revenue to be in the range of $450 million and $470 million, compared to analysts' estimates of $319.4 million - per data compiled by LSEG

** Expects 2026 U.S. net sales for constipation drug, Linzess, in the range of $1.13 billion and $1.18 billion, driven by improved net price and low-single digit percentage demand growth - IRWD

** Maintains 2025 revenue forecast to be in the range of $290 million and $310 million vs estimates of $307.1 million

** In the last 12 months, stock has slipped 23.9%

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))